CCL5 and neoplasm: Deoxycytidine blockade of TAMs impairs the cytotoxic activity of gemcitabine in PDAC tumor cells, and activation of the CCL5/CCR5/Sp1/CD44 signaling pathway in TAMs also inhibits the antitumor efficacy of gemcitabine.